MA43158B1 - Composés oxa-diazadispiro possédant une activité contre la douleur - Google Patents

Composés oxa-diazadispiro possédant une activité contre la douleur

Info

Publication number
MA43158B1
MA43158B1 MA43158A MA43158A MA43158B1 MA 43158 B1 MA43158 B1 MA 43158B1 MA 43158 A MA43158 A MA 43158A MA 43158 A MA43158 A MA 43158A MA 43158 B1 MA43158 B1 MA 43158B1
Authority
MA
Morocco
Prior art keywords
compounds
oxa
diazadispiro
activity against
against pain
Prior art date
Application number
MA43158A
Other languages
English (en)
Inventor
Carmen Almansa-Rosales
Marina Virgili-Bernado
Carlos Alegret-Molina
Original Assignee
Esteve Pharmaceuticals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Pharmaceuticals Sa filed Critical Esteve Pharmaceuticals Sa
Publication of MA43158B1 publication Critical patent/MA43158B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La présente invention concerne des composés oxa-diazaspiro ayant une activité pharmacologique par rapport au récepteur sigma (s), des procédés de préparation de ces composés, des compositions pharmaceutiques les comprenant, ainsi que leur utilisation thérapeutique, en particulier pour traiter la douleur.
MA43158A 2015-10-23 2016-10-21 Composés oxa-diazadispiro possédant une activité contre la douleur MA43158B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15382523 2015-10-23
EP16784795.3A EP3365346B1 (fr) 2015-10-23 2016-10-21 Composés oxa-diazadispiro possédant une activité contre la douleur
PCT/EP2016/001742 WO2017067664A1 (fr) 2015-10-23 2016-10-21 Composés oxa-diazaspiro ayant une activité contre la douleur

Publications (1)

Publication Number Publication Date
MA43158B1 true MA43158B1 (fr) 2020-03-31

Family

ID=54364221

Family Applications (1)

Application Number Title Priority Date Filing Date
MA43158A MA43158B1 (fr) 2015-10-23 2016-10-21 Composés oxa-diazadispiro possédant une activité contre la douleur

Country Status (30)

Country Link
US (1) US10689398B2 (fr)
EP (1) EP3365346B1 (fr)
JP (1) JP6884973B2 (fr)
KR (1) KR20180073638A (fr)
CN (1) CN108349998B (fr)
AR (1) AR106448A1 (fr)
AU (1) AU2016343551A1 (fr)
BR (1) BR112018007269A2 (fr)
CA (1) CA2999925A1 (fr)
CO (1) CO2018004803A2 (fr)
CY (1) CY1122708T1 (fr)
DK (1) DK3365346T3 (fr)
ES (1) ES2775522T3 (fr)
HR (1) HRP20200309T1 (fr)
HU (1) HUE047997T2 (fr)
IL (1) IL258370A (fr)
LT (1) LT3365346T (fr)
MA (1) MA43158B1 (fr)
ME (1) ME03636B (fr)
MX (1) MX2018004777A (fr)
PH (1) PH12018500682A1 (fr)
PL (1) PL3365346T3 (fr)
PT (1) PT3365346T (fr)
RS (1) RS59956B1 (fr)
RU (1) RU2018118399A (fr)
SG (1) SG11201802988XA (fr)
SI (1) SI3365346T1 (fr)
TN (1) TN2018000091A1 (fr)
TW (1) TW201731853A (fr)
WO (1) WO2017067664A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201615643A (zh) 2014-06-02 2016-05-01 伊史帝夫博士實驗室股份有限公司 具有多重模式抗疼痛活性之１－氧雜－４，９－二氮雜螺十一烷化合物之烷基與芳基衍生物
PL3365346T3 (pl) 2015-10-23 2020-06-01 Esteve Pharmaceuticals, S.A. Związki oksa-diazaspiro o działaniu przeciwbólowym

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3481942A (en) 1968-09-06 1969-12-02 Smithkline Corp Oxa-diazaspiro(4.5)decane compounds
US4353900A (en) * 1981-10-19 1982-10-12 Syntex (U.S.A.) Inc. 9-(Arylalkyl or aroylalkyl)-1-oxa-4,9-diazaspiro(5.5)undecan-3-ones
WO1993013101A1 (fr) * 1991-12-27 1993-07-08 Yoshitomi Pharmaceutical Industries, Ltd. Compose de pyridonecarboxylate, son utilisation pharmaceutique et compose spiro
US6114541A (en) 1997-03-10 2000-09-05 Hoffmann-La Roche Inc. Method for the preparation of α-Bromo-Lactam derivatives
EP1461339B1 (fr) 2001-12-28 2010-04-28 Acadia Pharmaceuticals Inc. Composes spiroazacycliques utilises comme modulateurs du recepteur de monoamine
WO2005046589A2 (fr) * 2003-11-07 2005-05-26 Chiron Corporation Sels de composes de quinolinone acceptables d'un point de vue pharmaceutique et presentant des proprietes pharmaceutiques ameliorees
EP1634873A1 (fr) 2004-08-27 2006-03-15 Laboratorios Del Dr. Esteve, S.A. Inhibiteurs des récepteurs sigma
DE102005030051A1 (de) 2005-06-27 2006-12-28 Grünenthal GmbH Substituierte 1-Oxa-3,8-diazaspiro[4,5]-decan-2-on-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
PT1961744E (pt) 2005-11-18 2013-05-15 Ono Pharmaceutical Co Composto que contém um grupo básico e sua utilização
EP1829869A1 (fr) 2006-03-02 2007-09-05 Laboratorios Del Dr. Esteve, S.A. Dérivés de 4,5,6,7-tétrahydrobenzo[b]thiophène et leur utilisaton comme ligands du récepteur sigma
WO2007124136A1 (fr) 2006-04-19 2007-11-01 Acadia Pharmaceuticals, Inc. Utilisation de 4-amino-piperidines pour le traitement des troubles du sommeil
EP1847542A1 (fr) 2006-04-21 2007-10-24 Laboratorios del Dr. Esteve S.A. Dérivés de spiro[benzopyran] ou de spiro[benzofuran] comme antagonistes du récepteur sigma
AU2008219980B2 (en) 2007-03-01 2012-01-12 Mitsubishi Tanabe Pharma Corporation Benzimidazole compound and pharmaceutical use thereof
EP1982714A1 (fr) 2007-04-16 2008-10-22 Laboratorios del Dr. Esteve S.A. Pyrano-pyrazole-aminés
EP2020414A1 (fr) 2007-06-20 2009-02-04 Laboratorios del Dr. Esteve S.A. Derivés spiro[piperidine-4,4'-thieno[3,2-c]pyran] et composés similaires en tant que inhibiteurs du recepteur sigma pour le traitement de pyschose
JP2010538003A (ja) 2007-08-29 2010-12-09 グラクソスミスクライン エルエルシー チアゾールおよびオキサゾールキナーゼ阻害薬
EP2070933A1 (fr) 2007-12-07 2009-06-17 Laboratorios del Dr. Esteve S.A. Composants triazoliques tricycliques
ES2394547T3 (es) 2008-02-06 2013-02-01 Astrazeneca Ab Compuestos
EP2460347A4 (fr) 2009-10-25 2014-03-12 Lg Electronics Inc Procédé pour traiter des informations de programme de diffusion et récepteur de diffusion
CN103517910B (zh) * 2011-03-14 2016-12-14 沃泰克斯药物股份有限公司 作为离子通道调节剂的吗啉-螺环哌啶酰胺
WO2012125813A1 (fr) 2011-03-16 2012-09-20 Access Business Group International Llc Humidificateur à désinfection par ultraviolets
EP2744333B1 (fr) 2011-08-19 2016-10-05 Glaxosmithkline Intellectual Property (No. 2) Limited Inhibiteurs d'acide gras synthase
US9751881B2 (en) 2013-07-31 2017-09-05 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
JP2017100951A (ja) 2014-04-04 2017-06-08 大正製薬株式会社 オキサゾリジノン及びオキサジナノン誘導体
TW201615643A (zh) * 2014-06-02 2016-05-01 伊史帝夫博士實驗室股份有限公司 具有多重模式抗疼痛活性之１－氧雜－４，９－二氮雜螺十一烷化合物之烷基與芳基衍生物
TW201615642A (zh) 2014-06-02 2016-05-01 伊史帝夫博士實驗室股份有限公司 具有多重模式抗疼痛活性的１－氧雜－４，９－二氮雜螺十一烷化合物之醯胺衍生物
TWI685497B (zh) 2014-06-02 2020-02-21 西班牙商伊史帝夫製藥公司 具有多重模式抗疼痛活性的１-氧雜-４,９-二氮雜螺十一烷化合物之烷基衍生物
EP3221315A1 (fr) 2014-11-21 2017-09-27 Laboratorios Del. Dr. Esteve, S.A. Composés de 1,9-diazaspiro-undécane à activité multimodale contre la douleur
PL3365346T3 (pl) 2015-10-23 2020-06-01 Esteve Pharmaceuticals, S.A. Związki oksa-diazaspiro o działaniu przeciwbólowym

Also Published As

Publication number Publication date
AU2016343551A1 (en) 2018-04-19
EP3365346B1 (fr) 2019-12-04
PH12018500682A1 (en) 2018-10-01
WO2017067664A9 (fr) 2017-06-29
BR112018007269A2 (pt) 2018-10-30
JP2018531263A (ja) 2018-10-25
CN108349998B (zh) 2021-10-29
DK3365346T3 (da) 2020-03-09
US20190002475A1 (en) 2019-01-03
CN108349998A (zh) 2018-07-31
HUE047997T2 (hu) 2020-05-28
RU2018118399A3 (fr) 2020-01-31
ME03636B (fr) 2020-07-20
PT3365346T (pt) 2020-03-05
RS59956B1 (sr) 2020-03-31
SI3365346T1 (sl) 2020-04-30
LT3365346T (lt) 2020-04-10
US10689398B2 (en) 2020-06-23
SG11201802988XA (en) 2018-05-30
MX2018004777A (es) 2018-06-19
EP3365346A1 (fr) 2018-08-29
CY1122708T1 (el) 2021-03-12
CA2999925A1 (fr) 2017-04-27
TN2018000091A1 (en) 2019-07-08
CO2018004803A2 (es) 2018-07-19
ES2775522T3 (es) 2020-07-27
RU2018118399A (ru) 2019-11-25
AR106448A1 (es) 2018-01-17
PL3365346T3 (pl) 2020-06-01
TW201731853A (zh) 2017-09-16
JP6884973B2 (ja) 2021-06-09
HRP20200309T1 (hr) 2020-06-12
WO2017067664A1 (fr) 2017-04-27
KR20180073638A (ko) 2018-07-02
IL258370A (en) 2018-05-31

Similar Documents

Publication Publication Date Title
AU2018236800B2 (en) DNA-PK inhibitors
EA201692177A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
NZ724878A (en) Compounds and compositions as toll-like receptor 7 agonists
EP3995581A3 (fr) Composés d'oligonucléotides pour traiter la pré-éclampsie et d'autres troubles angiogéniques
EA201691070A1 (ru) Новые трициклические соединения в качестве противораковых средств
PH12019502363A1 (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
EA201491530A1 (ru) Модуляторы рецепторов эстрогенов и их применение
MX2022016422A (es) Inhibidores de glicolato oxidasa para el tratamiento de enfermedades.
WO2015184257A3 (fr) Modulateurs de la transcription de petite molécule de bromodomaines
PH12017500401A1 (en) Therapeutic compounds as inhibitors of the orexin-1 receptor
MA47356A1 (fr) Dérivés d'isochromène utiles en tant qu'inhibiteurs des phosphoinositide 3-kinases
MX2012004078A (es) Compuestos y composiciones como moduladores de la actividad de gpr119.
PH12016500978A1 (en) Piperazine derivatives having multimodal activity against pain
MA35816B1 (fr) Dérivés d'aniline, leur préparation et leur application thérapeutique
PH12019501224A1 (en) Compositions for treatment of polycystic kidney disease
MA43158B1 (fr) Composés oxa-diazadispiro possédant une activité contre la douleur
MA43250B1 (fr) Composés d'oxadiazaspiro pour le traitement de l'abus et la dépendance aux drogues
EA202090549A1 (ru) Восстановление активности t-клеток посредством системы cd39/cd73
JO3621B1 (ar) مركبات وتركيبات على هيئة عوامل مساعدة لمستقبل 7 يشبه toll
MX2018004776A (es) Compuestos oxaazaespiricos con actividad contral el dolor.